Senate Committee Advances CDC Director Nomination Amid Concerns

NEW YORK (AP) — The Senate committee has progressed Dr. Erica Schwartz’s nomination to lead the Centers for Disease Control and Prevention (CDC). If confirmed, Schwartz would be the 22nd director, responsible for guarding Americans against preventable health risks. Her background includes medical and law degrees, a tenure as deputy surgeon general, and leadership in the U.S. Coast Guard.

The nomination confronted skepticism during a Senate Health, Education, Labor and Pensions Committee hearing, where concerns arose about her ability to resist political interference. Chairman Sen. Bill Cassidy, R-La., queried her readiness to challenge orders from health secretary Robert F. Kennedy Jr. that might conflict with scientific and public health standards. However, Cassidy later expressed confidence in Schwartz’s abilities after consultations.

The committee’s vote leaned along party lines, advancing Schwartz’s nomination, although some, like Sen. Bernie Sanders, I-Vt., opposed it. Sanders highlighted the need for officials in the Trump administration who stand firm against anti-science movements and conspiracy theories. The CDC has experienced significant employee reductions and leadership instability since Trump took office, eroding morale with politically inexperienced appointees.

Public health specialists remained cautiously optimistic about Schwartz’s nomination in April, pointing out her connection to Trump as opposed to Kennedy. Kennedy, initially a vocal critic of vaccines, attempted revisions to vaccine guidelines, some of which federal enforcement delayed. His efforts concerned Cassidy, who required assurances about maintaining the nation’s vaccine policies.

During her hearing, Schwartz was asked about her response to politically motivated directives. She affirmed her commitment to science but failed to challenge some actions taken by Kennedy. The National Public Health Coalition found her assurances lacking and called for explicit commitments regarding scientific independence and evidence-based vaccine policies.

Questions were also raised about Schwartz’s awareness of curtailed CDC programs aimed at reducing smoking and promoting vaccinations. She agreed on the lack of evidence linking vaccines to autism, yet resisted pledging to change a disputed CDC webpage on this issue. Modifications to this page were reported as a goodwill gesture, but inconsistencies remained in its language.

Dr. Georges Benjamin, of the American Public Health Association, viewed Schwartz as someone trying to balance competing demands. Despite disagreements, he continued to back her expertise and potential to enhance the CDC’s leadership and trust. Former CDC official Dr. Daniel Jernigan warned of continued leadership voids if Schwartz’s nomination falters, suggesting Kennedy’s ongoing influence on anti-science agendas.

Schwartz stands as the third nominee from Trump for CDC leadership in 18 months. The nomination process faced previous setbacks with Dr. David Weldon and temporary appointee Susan Monarez. Presently, the CDC is experiencing a series of temporary leadership through Health and Human Services officials.

The potential appointment of Sean Kaufman as assistant health secretary for preparedness and response garnered attention. Although his vaccine-skeptic statements caused concern, assurances were made about his role being devoid of influence over vaccine policy. Cassidy emphasized reforms in HHS to ensure science guides decisions, notwithstanding Kaufman’s past controversial remarks.

The Associated Press Health and Science Department, supported by grants from the Howard Hughes Medical Institute and the Robert Wood Johnson Foundation, clarified its independent control over content.